- Details
- In a discussion on the management of metastatic hormone-sensitive prostate cancer (mHSPC) Karim Fizazi joins Alicia Morgans in discussing when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of Paris-Saclay in Villej...
|
- Details
- Neal Shore joins Alicia Morgans to discuss pioneering work on establishing the importance of multidisciplinary teams in the management of urologic oncology patients. This was a plenary presentation at the AUA led by Leonard Gomella and Neal Shore and Michael Cookson as panelists. They discussed the importance of a collaborative approach to optimizing patient care. Drs. Morgans and Shore also highl...
|
- Details
- Alicia Morgans and Pedro Barata highlight real-world data understanding the metastatic prostate cancer setting, capturing data on patients treated for metastatic hormone-sensitive and then metastatic castration-resistant disease presented at ASCO GU 2022. Clinical trials presented over the past seven years have led to novel hormonal therapies as well as taxane based chemotherapy being approved for...
|
- Details
- Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...
|
- Details
- Alicia Morgans and Fred Saad discuss the ongoing ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARANOTE is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Dr. Saad gives a background on the trial. Biographies: Fred Saad, MD, FRCS...
|
- Details
- Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...
|
- Details
- Thomas Keane is joined by Heather Payne to discuss the management of metastatic hormone-sensitive prostate cancer. While treatment with androgen deprivation therapy (ADT) provides initial responses, progression is common and a large proportion of prostate cancer-related deaths occur among men initially diagnosed with metastatic disease. Dr. Payne focuses her discussion on multiple trials determini...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the recent analysis of the PEACE-1 study. The PEACE-1 study is a phase 3 trial evaluating abiraterone plus standard of care in M1 disease and local radiation therapy directed to the prostate primary. Dr. Fizazi discusses the study design and the first results he presented at ASCO 2021, specifically treatment with androgen deprivation therapy (ADT), docetaxel...
|
- Details
- Alicia Morgans with Arun Azad and Declan Murphy about an ongoing clinical trial exploring the use of Lutetium PSMA for treating newly diagnosed metastatic hormone-sensitive prostate cancer. Dr. Azad reveals that the trial aims to assess whether adding Lutetium PSMA to standard chemo-hormonal therapy improves efficacy. The study has garnered significant interest, enrolling over a quarter of its tar...
|
- Details
- In an abstract review session at the 2021 ASCO annual meeting, Lisa Horvath, PhD, MBBS, FRACP, reviewed 3 abstracts: PEACE-1, the SWOG S1216 trial, and the PEACE-III trial. She expanded her conversation about these three abstracts in a discussion with Alicia Morgans, MD, MPH. In the primary conversation about the PEACE-1 trial, Dr. Horvath discussed the main interest, in this phase III trial, to b...
|
